AZN / AstraZeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) more_horizontal

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to spee more_horizontal

In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day. more_horizontal

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact th more_horizontal

AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19. more_horizontal

Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healt more_horizontal

Employers which pay staff the Real Living Wage (RLW) will have to find an extra 10% after it was increased to £12 in the UK and £13.10 in London on more_horizontal

AstraZeneca PLC AZN, -1.22% AZN, +1.45% said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-adminis more_horizontal